Research
Dr. Daar has been involved in HIV research and patient care since the early days of the HIV/AIDS epidemic. His work has primarily focused on defining the pathogenesis of acute HIV infection as well as designing clinical trials to optimize treatment and overcome obstacles to maintaining control of HIV in clinical practice. His work has influenced treatment guidelines and led to him having consistent NIH support for most of the last 30 years. He was also one of the national leads in the development of COVID-19 therapeutics for nonhospitalized patients, along with participation in numerous prevention and treatment trials.
Biography
Dr. Eric S. Daar, M.D. is the Chief of the Division of HIV Medicine at Harbor-UCLA Medical Center, Investigator at The Lundquist Institute at Harbor-UCLA and Professor of Medicine at the David Geffen School of Medicine at UCLA. He is an Infectious Diseases-trained clinician-investigator with more than 30 years experience providing HIV care and conducting clinical and translational research related to HIV/AIDS and COVID-19. His research focus has been on the development and implementation of studies to address HIV pathogenesis and clinical questions related to optimal management of HIV infection as well as COVID-19. He has received research support from multiple sources including the NIH, site Principal Investigator for the Advancing Clinical Therapeutics Globally (formerly known as AIDS Clinical Trials Group, ACTG) Network at Lundquist Institute at Harbor-UCLA Medical Center. His research work has resulted in him authoring more than 300 peer-reviewed publications. He is also a member of the Health and Human Services Panel for Adult and Adolescent HIV Treatment Guidelines and the IDSA COVID-19 Treatment Guidelines Panel. He has also been honored as a Legend of The Lundquist Institute.